Skip to main content
OpenTrials
Completed

NCT Number: NCT01415180

Life After Pediatric Sepsis Evaluation

Sepsis represents the leading cause of childhood mortality worldwide. However, as distinct from adult medicine, there exists a large knowledge gap regarding long term health related quality of life (HRQL) and functional status (FS) following pediatric sepsis. This lack of sepsis outcomes data is critical because failure to identify children at risk for sepsis associated HRQL/FS deterioration may delay delivery of crucial rehabilitation medicine efforts to facilitate recovery. Moreover, failure to identify mechanisms of sepsis associated HRQL/FS deterioration may impede development of novel, effective interventions for these children. For the first time the LAPSE investigation will quantify deterioration of HRQL/FS among children surviving sepsis. We will measure the incidence, magnitude and duration of HRQL/FS alterations associated with pediatric septic shock, and examine clinical, sociodemographic, and parent/family factors potentially associated with such adverse outcomes. Because sepsis affects a heterogeneous group of children, long term morbidity associated with sepsis likely depends on premorbid health status and parent, family and home characteristics, as well as children's clinical course during sepsis critical illness. Mechanisms underlying adverse sepsis outcomes among children are poorly understood at this time. Clinically multiple organ dysfunction syndrome (MODS) has been clearly linked to sepsis mortality. To begin to understand pathophysiology underlying pediatric sepsis morbidity, this investigation will seek to identify evidence for association of HRQL/FS alterations following sepsis with intensity and duration of sepsis mediated organ dysfunction as well as with pre-existing comorbidities and parent, family, and home characteristics. The long-term goal of this research program is to timely identify children at high risk of sepsis mediated HRQL/FS deterioration and ultimately to design effective interventions to minimize such risk. The primary objectives of this investigation are to comprehensively characterize HRQL/FS trajectory and to critically examine the potential role of sepsis mediated organ dysfunction as well as pre-existing comorbidities and parent, family, and home characteristics as risk factors for the adverse outcomes. The central hypothesis is that intensity of sepsis organ dysfunction will predict magnitude of HRQL/FS deterioration. We also hypothesize that the trajectory towards baseline HRQL/FS following the sepsis event will also depend on pre-existing co-morbidities and parent, family, and home, and characteristics. Knowledge of these potential mechanisms will ultimately facilitate development of targeted interventions to maximize HRQL/FS among children surviving sepsis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 month–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Phoenix Children's Hospital, Phoenix, Arizona, United States

Loading trial locations.

About this study

In-hospital pediatric sepsis mortality has decreased substantially, but long-term mortality and morbidity among children initially surviving sepsis, is unknown. Accordingly, the Life After Pediatric Sepsis Evaluation investigation was conducted to describe the trajectory of mortality and health-related quality of life morbidity and critical illness factors associated with these outcomes for children encountering community-acquired septic shock.

Design: Prospective, cohort-outcome study, conducted 2013-2017. Setting: Twelve academic pediatric intensive care units (PICUs) in the United States.

Patients: Critically ill children, 1 month to 18 years, with community-acquired septic shock requiring vasoactive-inotropic support. Interventions: Demographic, infection, and illness severity data were collected at PICU admission. Organ dysfunction and resource utilization data were collected during PICU stay. Serial parent proxy-report health-related quality of life assessments were obtained at baseline, 7 days, and 1, 3, 6, and 12 months following PICU admission utilizing the Pediatric Quality of Life Inventory or Stein-Jessop Functional Status Scale.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 44 weeks EGA to 18 years
  • Admitted to the PICU for the sepsis event
  • Evidence of SIRS including fever/ hypothermia and leukocytosis/leukopenia
  • Documented or suspected infection
  • Cardiovascular organ dysfunction with need for vasoactive-inotropic support

Exclusion criteria

  • Lack of commitment to aggressive sepsis therapy OR
  • Ward of the state OR
  • Sepsis event associated with a PICU-acquired nosocomial infection OR
  • Parents do not speak English or Spanish OR
  • Previously enrolled in the LAPSE study
  • Enrollment not possible within 12 hours of PICU admission

Treatment and study plan

Primary outcomes

  1. Specific Aim 1: Measure alterations in HRQL/FS longitudinally among children with septic shock.

    Time frame: Baseline, PICU discharge, 1, 3, 6, 12 months following PICU admission for sepsis

    Hypotheses related to this specific aim include:

    1.1 A majority of children with septic shock will demonstrate declination of generic HRQL/FS comparing baseline and one month post-enrollment measures. [Incidence]

    1.2 Significant deterioration in generic HRQL/FS will occur among children with septic shock comparing baseline and one month post-enrollment measures. [Magnitude]

    1.3 Normalization of HRQL/FS will be observed by 12 months for the majority of children surviving septic shock. [Duration]

Secondary outcomes

  1. Specific Aim 2: Determine the association between the magnitude of septic shock related HRQL/FS deterioration with validated measures of sepsis-mediated organ dysfunction.

    Time frame: Baseline, PICU discharge, 1, 3, 6, 12 months following PICU admission for sepsis

    Hypotheses related to this specific aim include:

    2.1 Magnitude of septic shock related generic HRQL/FS deterioration will be associated with area under the curve of validated organ dysfunction measures assessed daily during PICU stay for the sepsis event.

  2. Specific Aim 3: Describe the association between longitudinal changes in HRQL/FS following septic shock with measures of parent, family, and home characteristics and pre-existing comorbidities.

    Time frame: Baseline, PICU discharge, 1, 3, 6, 12 months following PICU admission for sepsis

    Hypotheses related to this specific aim include:

    3.1 Family and home characteristics (socio-economic status, parental educational attainment, family function, parental distress, and insurance status) will be associated with duration and magnitude of HRQL/FS alterations.

    3.2 Complexity of chronic comorbid conditions will be associated with duration and magnitude of HRQL/FS alterations

Sponsors and collaborators

Lead sponsor

Seattle Children's Hospital

Other

Collaborators

  • C.S. Mott Children's Hospital
  • Children's Hospital Los Angeles
  • Children's Hospital of Michigan
  • Children's Hospital of Philadelphia
  • Children's National Research Institute
  • Phoenix Children's Hospital
  • Texas A&M University
  • The National Collaborative Pediatric Critical Care Research Network
  • University of California, Los Angeles
  • University of Pittsburgh

Registry information

Acronym: LAPSE

Important dates

Study start
2013
Primary completion
2018
Study completion
2018
First posted
Aug 11, 2011
Registry last updated
Dec 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.